Hyderabad’s economy runs on three tracks that rarely appear together in a single city: a Global Capability Centre hub second only to Bengaluru, the country’s largest pharmaceutical and life sciences cluster through Genome Valley, and a growing base of aerospace, defence and deep-tech ventures. Each of these tracks generates valuation requirements of a different character. A Registered Valuer in Hyderabad who understands only the startup funding playbook will miss most of what the city’s economy actually needs. This guide covers when a Registered Valuer is mandatory, who else may certify a valuation, and what each of Hyderabad’s principal sectors requires, under the law as it stands from 1 April 2026.
1. Why Hyderabad Companies Need a Registered Valuer
The Registered Valuer (RV) framework, established under Section 247 of the Companies Act, 2013 and governed by the Companies (Registered Valuers and Valuation) Rules, 2017, applies uniformly across India. What differs by city is the mix of transactions that trigger it. In Hyderabad, that mix is shaped by three structural features of the local economy.
1.1 A GCC Hub With Its Own Valuation Pattern
Hyderabad hosts several hundred Global Capability Centres across HITEC City, Gachibowli and the Financial District, employing well over 300,000 professionals. Unlike a venture-funded startup, a GCC’s Indian entity rarely raises external equity rounds — its valuation events instead cluster around related-party transactions with the foreign parent, transfer pricing documentation for intercompany services, and, where the Indian entity runs a local ESOP alongside the parent’s global equity plan, the valuation of that local scheme. These are quieter, more infrequent triggers than a startup’s funding cycle, but they carry real regulatory weight under both the Companies Act and India’s transfer pricing rules.
1.2 India’s Largest Pharmaceutical and Life Sciences Cluster
Genome Valley anchors Hyderabad’s position as India’s largest pharmaceutical and life sciences hub, spanning bulk drug manufacturing, vaccine production, contract research and biotechnology. These companies present a valuation profile almost the inverse of a typical startup: asset-heavy balance sheets dominated by plant, machinery and manufacturing infrastructure, established revenue histories, and — for listed group entities or those preparing for an IPO — merger, demerger and related-party transaction valuations under Sections 230 to 232 of the Companies Act. Net Asset Value approaches carry more weight here than in a pure technology valuation.
1.3 Aerospace, Defence and Deep-Tech
Hyderabad has built a genuine aerospace and defence manufacturing base alongside a growing cluster of space-tech and deep-tech ventures, several incubated through T-Hub. These companies combine long, capital-intensive development cycles with small, specialised engineering teams and — in some cases — government contracts or IDEX grants. Pre-revenue valuation for this group typically departs from a standard DCF in favour of milestone-based or risk-adjusted approaches, and any equity issued to non-resident investors or directors requires care around foreign ownership and security clearance considerations alongside the standard Registered Valuer requirement.
PRACTICAL CONTEXT — TS-iPASS AND THE STARTUP TRACK
Telangana’s TS-iPASS single-window clearance system gives Hyderabad-based startups one of the fastest paths from incorporation to operational scale in India, with most departmental approvals guaranteed within 15 to 30 working days. As Hyderabad’s venture-funded companies move through successive rounds, they follow the same Companies Act valuation triggers seen in any Indian startup hub — preferential allotments, ESOP grants, and eventual pre-IPO restructuring — but they sit alongside, not in place of, the GCC and pharma patterns described above.
Marcken Consulting delivers the IBBI Registered Valuer (Securities or Financial Assets) report and, where the transaction also requires it, a Merchant Banker certificate issued by a SEBI-registered Category-I Merchant Banker, so that a Hyderabad company’s statutory valuation requirements — whether GCC, pharma, deep-tech or startup — are addressed in a single coordinated engagement.
2. Quick Reference: When Does a Hyderabad Company Need a Valuation, and From Whom?
The following table sets out the primary statutory triggers requiring a valuation, together with the professional whose certificate satisfies each requirement. A Registered Valuer’s report will not satisfy an income-tax requirement, and a Merchant Banker’s certificate will not satisfy a Companies Act requirement — the two are not interchangeable. For a comprehensive overview of valuation applicability across Indian law, see: Valuation Applicability in India.
| Situation | Applicable Law | Who Must Certify |
|---|---|---|
| Preferential allotment of shares (funding round) | Section 62(1)(c) read with Rule 13, Companies Act, 2013 | Registered Valuer (SFA) |
| Private placement of securities | Section 42 read with Rule 14, Companies (Prospectus and Allotment of Securities) Rules, 2014 | Registered Valuer (SFA) |
| Setting the ESOP exercise price | Section 62(1)(b) read with Rule 12, Companies Act | Independent fair value; a Registered Valuer report is standard practice |
| Merger, demerger or scheme of arrangement (common in pharma group restructuring) | Sections 230 and 232, Companies Act | Registered Valuer (SFA) |
| Purchase of minority shareholding (90 per cent acquirer) | Section 236, Companies Act | Registered Valuer (SFA) |
| IBC / CIRP fair value and liquidation value | Regulations 27 and 35, IBBI (CIRP) Regulations, 2016 | Two Registered Valuers per asset class (SFA / L&B / P&M) |
| FDI: issue of shares to a non-resident investor | FEMA (Non-Debt Instruments) Rules, 2019 | Chartered Accountant, SEBI-registered Merchant Banker or practising Cost Accountant (not an RV) |
| ESOP perquisite FMV on exercise | Rule 15, Income-tax Rules, 2026, read with Section 17(1), Income-tax Act, 2025 | SEBI-registered Category-I Merchant Banker (not an RV) |
| FMV of unquoted equity shares for receipt below value / transfer below value | Rule 57, Income-tax Rules, 2026, for the purposes of Section 92(2)(m) and Section 79, Income-tax Act, 2025 | NAV formula prescribed by Rule 57; feeds into the Merchant Banker or accountant certification for the specific transaction |
| Related-party transaction / transfer pricing documentation (GCC intercompany services) | Sections 92 to 92F, Income-tax Act, 1961, and corresponding provisions of the Income-tax Act, 2025 | Transfer pricing specialist, with independent valuation as a supporting input |
The table highlights a distinction that Hyderabad companies frequently get wrong, particularly GCCs new to Indian statutory requirements: a Registered Valuer’s report and a Merchant Banker’s certificate serve different purposes and are not substitutes for one another. For a full breakdown of income-tax provisions requiring a valuation report, see: Income Tax Act sections requiring valuation reports.
3. Valuation Requirements by Track: Startup, GCC and Pharma
Unlike a single-track startup hub, Hyderabad’s valuation calendar depends heavily on which of the city’s three principal tracks a company sits on.
3.1 The Startup Track: Seed Through Pre-IPO
- Seed and Series A: Angel and institutional rounds are typically structured as a preferential allotment under Section 62(1)(c) read with Rule 13, or a private placement under Section 42 read with Rule 14, both requiring a Registered Valuer’s report. Early ESOP grants under Section 62(1)(b) read with Rule 12 call for an independent fair value to support the exercise price.
- Growth stage: Secondary transfers and ESOP buybacks should be supported by a fresh valuation for each event rather than a recycled prior-round figure, given how quickly HITEC City and Gachibowli-based technology valuations can move between rounds.
- Pre-IPO: Mergers, demergers and scheme-of-arrangement valuations under Sections 230 to 232 require Registered Valuer reports filed with the NCLT, and the company’s ESOP scheme must align with the SEBI SBEB Regulations, 2021 ahead of listing.
3.2 The GCC Track: Set-Up Through Steady State
- Entity set-up: Where a GCC establishes its Indian entity via a wholly owned subsidiary structure, initial share subscription by the foreign parent falls under FEMA’s FDI pricing rules rather than a Registered Valuer requirement — the certifying professional is a Chartered Accountant, a SEBI-registered Merchant Banker or a practising Cost Accountant.
- Ongoing related-party transactions: Intercompany service agreements, cost-plus arrangements and cross-charges between the Indian GCC and its foreign parent fall under India’s transfer pricing regime (Sections 92 to 92F). An independent valuation of the arm’s length price is a standard supporting input, prepared alongside the transfer pricing study.
- Local ESOP or RSU decisions: Where the GCC chooses to run a local ESOP scheme for the Indian entity rather than relying solely on the parent’s global equity plan, the same Section 62(1)(b) and Rule 15 requirements apply as for any other Hyderabad company. See our companion guide: ESOP Consultant in Hyderabad.
3.3 The Pharma and Manufacturing Track
- Capital-intensive NAV valuations: Where an established pharma or manufacturing company requires a valuation for a Companies Act transaction, the Net Asset Value approach carries proportionally more weight than for an asset-light technology company, given the scale of plant, machinery and manufacturing infrastructure on the balance sheet.
- Group restructuring: Many Genome Valley companies sit within larger pharmaceutical groups. Mergers, demergers and internal restructuring among group entities require Registered Valuer reports under Sections 230 to 232, and, where a listed parent is involved, careful independence from any related-party conflict in the valuation process.
- IP and licensing valuation: Cross-border licensing and royalty arrangements between Hyderabad pharma companies and foreign partners carry FEMA and transfer pricing implications and typically require valuation methodologies such as Relief-from-Royalty, alongside conventional DCF or NAV.
4. ESOP and Share Valuation in Hyderabad
ESOP valuation is one of the most common Registered Valuer engagements across all three of Hyderabad’s tracks. It involves three distinct requirements that rest on different professional credentials. For a complete guide, see: How is ESOP Valuation Calculated?
- Grant-date fair value, Ind AS 102: The fair value of the option for accounting purposes, computed using an option-pricing model such as Black-Scholes-Merton, supporting the share-based payment expense recognised in the financial statements.
- Exercise price determination, Companies Act: ESOPs are issued under Section 62(1)(b) read with Rule 12, which requires the exercise price to be determined in conformity with applicable accounting policies. An independent fair value of the underlying shares is the standard way to evidence this, and a Registered Valuer’s report becomes mandatory where the same shares are also allotted under Section 62(1)(c).
- Perquisite fair market value, Rule 15: With effect from 1 April 2026, the fair market value of unlisted shares on the exercise date, for computing the perquisite taxable under Section 17(1) of the Income-tax Act, 2025, must be determined by a SEBI-registered Category-I Merchant Banker on the exercise date, or on an earlier date not more than 180 days before it. This is the successor to Rule 3(8)/3(9) of the Income-tax Rules, 1962. Marcken Consulting coordinates the Registered Valuer’s report and the Merchant Banker’s certificate within a single engagement.
5. Common Valuation Mistakes Made by Hyderabad Companies
The following mistakes recur across Hyderabad’s different company types, though the specific pattern varies by track. For a broader view of who can issue valuation reports in India, see: Who Can Issue a Business Valuation Report in India?
| Common Mistake | Consequence | Correct Approach |
|---|---|---|
| GCCs treating parent-level equity compensation as sufficient without addressing the Indian entity’s own Companies Act requirements | Any local share allotment or ESOP grant by the Indian entity still requires a Registered Valuer’s report; the parent’s global equity plan does not substitute for it | Confirm with counsel whether the Indian entity has made any local allotments requiring a Section 62 valuation |
| Using a plain CA certificate instead of a Registered Valuer’s report for a preferential allotment | Does not satisfy Section 62(1)(c) read with Rule 13, or Section 247; the allotment is open to regulatory challenge | Engage an IBBI-registered Registered Valuer for all Companies Act allotments |
| Using a Registered Valuer’s report for the income-tax perquisite FMV on ESOP exercise | Rule 15 of the Income-tax Rules, 2026 requires the FMV on the exercise date to be determined by a Category-I Merchant Banker; TDS computed on an RV-based FMV may be challenged | Obtain a Category-I Merchant Banker certificate for the perquisite FMV |
| Applying a DCF-heavy methodology to an asset-heavy pharma or manufacturing entity | Understates or overstates value where plant, machinery and manufacturing infrastructure dominate the balance sheet | Weight NAV appropriately alongside DCF for capital-intensive businesses |
| Citing repealed law (Rule 3(8), Rule 11UA, Section 56(2)(x)) in a valuation report for a transaction dated on or after 1 April 2026 | The report cites provisions no longer in force; a reviewing officer or diligence team will flag it | Cite Rule 15, Rule 57, Section 92(2)(m) and Section 79 of the current framework for any transaction from 1 April 2026 onward |
6. Why Hyderabad Companies Engage Marcken Consulting as their Registered Valuer
Marcken Consulting LLP is an Ahmedabad-headquartered chartered accountancy firm providing valuation and corporate advisory services to companies across India, including an active Hyderabad client base spanning GCCs, pharma and life sciences companies, and venture-funded startups.
- IBBI Registered Valuer, Securities or Financial Assets: CA Murli Chandak is registered with IBBI as a Registered Valuer in the SFA class, the mandatory credential for Companies Act and IBC valuations across all three of Hyderabad’s principal tracks.
- Merchant Banker certificates: Where a transaction also requires a certificate under the Income-tax Act (Rule 15 for ESOP perquisites, or Rule 57 for FMV of unquoted shares), or a FEMA pricing certificate, that certificate is issued by a SEBI-registered Category-I Merchant Banker within the same coordinated engagement.
- Sector fluency: Experience spanning GCC subsidiaries, pharmaceutical and life-sciences companies, deep-tech and aerospace ventures, and venture-funded startups — the principal sectors that define Hyderabad’s economy.
- Track-appropriate methodology: DCF-led models for technology and services companies, NAV-weighted models for asset-heavy pharma and manufacturing entities, and milestone-based or risk-adjusted approaches for pre-revenue deep-tech ventures.
- Cross-border capability: Support for GCCs and startups with US or other foreign parent structures, including transfer pricing-adjacent valuation inputs and 409A-equivalent reports where required. See: Can an Indian Valuer do a 409A Valuation?
- Current on the law: All engagements reflect the Income-tax Act, 2025 and Income-tax Rules, 2026 as applicable from 1 April 2026, and the SEBI amendments effective 2 January 2026.
- Speed and confidentiality: Typical turnaround of 5 to 10 working days for share valuation reports from receipt of complete data, with remote engagement by default.
7. Frequently Asked Questions: Registered Valuer in Hyderabad
Q1. Does a Hyderabad-based GCC need an Indian Registered Valuer if its parent company already has its own equity plan?
A: It depends on what the Indian entity itself does. If the GCC’s Indian subsidiary only ever receives capital infusions from its foreign parent and never allots shares or ESOPs locally, the Registered Valuer requirement may not arise at the Indian entity level, though FEMA pricing compliance still applies to the parent’s share subscription. If the Indian entity runs its own local ESOP scheme or makes any preferential allotment, the standard Section 62 Registered Valuer requirements apply in full, regardless of what equity compensation the parent offers globally.
Q2. What valuation methodology applies to a Genome Valley pharma company with significant manufacturing assets?
A: For an established, asset-heavy pharma or manufacturing company, Net Asset Value typically carries more weight than it would for a technology company, given the scale of plant, machinery and manufacturing infrastructure on the balance sheet. A Weighted Average Value combining DCF (for the going-concern earning capacity) and NAV (for the underlying asset base) is common. For companies with significant patents, licensed technology or regulatory approvals, Relief-from-Royalty or Multi-Period Excess Earnings methodologies may also be applied to isolate the value of specific intangible assets.
Q3. Is a Registered Valuer’s report required for a pre-revenue Hyderabad deep-tech or aerospace company?
A: Yes, the same Companies Act triggers apply — any preferential allotment or private placement of shares requires a Registered Valuer’s report, regardless of whether the company has commercial revenue. What differs is the methodology: for a pre-revenue deep-tech or aerospace company, conventional DCF is difficult to apply, and the valuer typically uses risk-adjusted NPV, the scorecard method, or milestone-based approaches tied to technical de-risking events, documenting the departure from conventional DCF clearly in the report.
Q4. Can the same valuation report be used for both the Companies Act allotment and the income-tax perquisite calculation?
A: No. These are two separate regulatory requirements with different prescribed credentials. The Companies Act allotment requires a report from an IBBI-registered Registered Valuer. The income-tax perquisite calculation on ESOP exercise requires a certificate from a Category-I Merchant Banker under Rule 15 of the Income-tax Rules, 2026. The two can be coordinated within a single engagement, but they remain separate documents serving separate regulatory purposes. See: IBBI Registered Valuer vs. SEBI Merchant Banker, full comparison.
Q5. Is a Registered Valuer required for a merger between two Hyderabad pharma group entities?
A: Yes. Sections 230 and 232 of the Companies Act, 2013 require a Registered Valuer’s report to determine the share exchange ratio and the valuation of the entities involved in any merger, demerger or scheme of arrangement, filed as part of the NCLT application. This is common among Genome Valley companies that sit within larger pharmaceutical group structures and undertake periodic internal reorganisation.
Q6. How quickly can Marcken Consulting deliver a valuation for a Hyderabad company?
A: The typical turnaround for a share valuation, covering both the Registered Valuer’s report and, where required, the Merchant Banker’s certificate, is 5 to 10 working days from receipt of complete data. Required data includes audited financial statements for the last 3 to 5 years, management projections, the current cap table, the memorandum and articles of association, and a description of the business. Expedited turnaround is available for time-sensitive events by prior arrangement.
8. Engage Marcken Consulting as Your Registered Valuer in Hyderabad
Whether you are a HITEC City startup preparing a funding round, a GCC finance team addressing your first local ESOP grant, a Genome Valley pharma company restructuring within a larger group, or a deep-tech venture navigating pre-revenue valuation, Marcken Consulting provides the regulatory credentials and technical depth to deliver compliant, defensible valuation reports. For ESOP-specific guidance, see our companion guide: ESOP Consultant in Hyderabad.
A preliminary discussion covering the purpose of the valuation, the applicable regulatory framework, the timeline and the data available is available at no charge and typically takes 30 minutes.
Reach out to us at: marckenconsulting.com
Marcken Consulting LLP — IBBI-Registered Valuer (Securities or Financial Assets) | Ahmedabad
Phone: +91 99980 59923 / +91 99985 39902
Email: crm@marckenconsulting.com
Disclaimer: This article is intended for general informational purposes only and does not constitute legal, tax, or financial advice. Readers are advised to consult a qualified professional before acting on any information contained herein. The statutory provisions referred to above are subject to amendment; please verify the current position at the time of acting.
